Tetraphase Pharmaceuticals to Present New Clinical and Preclinical Research on Its Antibiotic Portfolio at ICAAC

- Presentations Include Phase 2 Data on Lead Agent Eravacycline (TP-434) as well as Laboratory Evaluations of TP-271 and Novel 8-Heterocycle Substituted Tetracyclines -

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep 5, 2012 - Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, announced today that results of new research on several of its next-generation tetracycline antibiotics will be presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentations will include late-breaking results of a Phase 2 clinical trial of the company's lead agent, eravacycline (TP-434), and chemical and biological evaluations of other novel tetracyclines in the company's portfolio. ICAAC will be held September 9-12, 2012, in San Francisco, CA.

“We are very excited about the presentation of results from our Phase 2 clinical study of intravenous (I.V.) eravacycline in complicated intra-abdominal infections,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals. “Even as we focus our efforts on late-stage clinical development of eravacycline, including the clinical program for a potential oral step-down therapy, we are also advancing other promising compounds from our pipeline of novel tetracyclines to address multidrug-resistant pathogens and difficult-to-treat infections.”

Poster presentations scheduled for ICAAC include:

“Efficacy and Safety of TP-434 versus Ertapenem in Complicated Intra-Abdominal Infection (cIAI).” [L1-1647a]

 

Tuesday, September 11, 2012, 11:15 a.m. - 1:15 p.m. Poster Session 186, Endocarditis and Other Invasive Infections: (Exhibit Halls A-C)
 
“TP-434 is Active In Vitro Against Biofilms Formed by Uropathogenic Escherichia coli.” [E-777]

 

Monday, September 10, 2012, 11:15 a.m. - 1:15 p.m. Poster Session 093, Cornucopia of in Vitro Activity: (Exhibit Halls A-C)
 
“Susceptibility of Tetracyclines to TN1721-Associated and Plasmid RP1-Associated Tet(A) Resistance is Dependent on Expression Level and Not Primary Structure.” [C1-675]
Monday, September 10, 2012, 11:15 a.m. - 1:15 p.m. Poster Session 086, Resistance by Efflux/Quinolone Resistance: (Exhibit Halls A-C)
 
“Novel 8-Heterocycle Substituted Tetracyclines are Potent and Broad Spectrum Antibacterial Agents with Oral Bioavailability.” [F-1526]
Tuesday, September 11, 2012, 11:15 a.m. - 1:15 p.m. Poster Session 177, Novel Antimicrobial Approaches and Agents: (Exhibit Halls A-C)
 
“TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity Against Community-Acquired Bacterial Respiratory and Biothreat Pathogens.” [F-1525]
Tuesday, September 11, 2012, 11:15 a.m. - 1:15 p.m. Poster Session 177, Novel Antimicrobial Approaches and Agents: (Exhibit Halls A-C)
About Eravacycline (TP-434)

Eravacycline, the lead product candidate in Tetraphase's clinical pipeline, is a potent new antibiotic effective against multidrug-resistant (MDR) gram-negative pathogens. Eravacycline is also effective against the broadest spectrum of other difficult-to-treat bacterial pathogens, including MDR gram-positive, anaerobic, and atypical species. Safe and well tolerated, eravacycline's spectrum and pharmacokinetic properties are consistent with its use as a once-daily monotherapy.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug-resistant and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of I.V. and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit http://www.tphase.com.

 

Contact: Sam Brown Inc.
Media Contact:
Mike Beyer, 773-463-4211
beyer@sambrown.com

 

Posted: September 2012

View comments

Hide
(web4)